

## INDEX

- (1) List containing one meeting between FDA and Wyeth Pharmaceuticals.

November 19, 2004 – Memorandum of Meeting

Wyeth representatives and FDA discussed issues surrounding the withdrawal of ProHeart®6 from the market.

Participants:

Wyeth

Bob Essner, Chairman, president, and Chief Executive Officer  
Jeff Levitt, V.P. and Chief Counsel, Regulatory and Research  
Gerald Fisher, Senior V.P., Drug Safety and Metabolism

FDA

Lester M. Crawford, Acting Commissioner of Food and Drugs  
Dan Troy, Chief Counsel, FDA  
Dana Delman, Policy Analyst, Office of the Executive Secretariat